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OBJECTIVE — Our aim was to evaluate the long-term effects of transplanted islets on dia-
betic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients.
RESEARCH DESIGN AND METHODS — A total of 34 type 1 diabetic kidney-
transplanted patients underwent islet transplantation and were divided into two groups: suc-
cessful islet-kidney transplantation (SI-K; 21 patients, fasting C-peptide serum concentration
0.5 ng/ml for 1 year) and unsuccessful islet-kidney transplantation (UI-K; 13 patients, fasting
C-peptide serum concentration0.5 ng/ml). Patients cumulative survival, cardiovascular death
rate, and atherosclerosis progression were compared in the two groups. Skin biopsies, endothe-
lial dependent dilation (EDD), nitric oxide (NO) levels, and atherothrombotic risk factors [von
Willebrand factor (vWF) and D-dimer fragment (DDF)] were studied cross-sectionally.
RESULTS — The SI-K group showed a significant better patient survival rate (SI-K 100, 100,
and 90% vs. UI-K 84, 74, and 51% at 1, 4, and 7 years, respectively, P  0.04), lower cardio-
vascular death rate (SI-K 1/21 vs. UI-K 4/13, 2  3.9, P  0.04), and lower intima-media
thickness progression than the UI-K group (SI-K group: 1–3 years 13  30 m vs. UI-K
group: 1–3 years 245 20 m, P 0.03) with decreased signs of endothelial injuring at skin
biopsy. Furthermore, the SI-K group showed a higher EDD than the UI-K group (EDD: SI-K
7.8 4.5% vs. UI-K 0.5 2.7%, P 0.02), higher basal NO (SI-K 42.9 6.5 vs. UI-K 20.2
6.8 mol/l, P 0.02), and lower levels of vWF (SI-K 138.6 15.3 vs. UI-K 180.6 7.0%, P
0.02) and DDF (SI-K 0.61  0.22 vs. UI-K 3.07  0.68 g/ml, P  0.01). C-peptide–to–
creatinine ratio correlated positively with EDD and NO and negatively with vWF and DDF.
CONCLUSIONS — Successful islet transplantation improves survival, cardiovascular, and
endothelial function in type 1 diabetic kidney-transplanted patients.
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I slet transplantation, particularly afterkidney transplantation, is an alterna-tive to pancreas transplantation to re-
store endogenous insulin secretion (1–7).
Islet transplantation is a safe procedure
leading to an improvement of glycometa-
bolic control and of protein and lipid me-
tabolism (1,3,6–8). The benefits of the
improvement of glycometabolic control
alone on macroangiopathy are unknown
(9,10).
Patients with type 1 diabetes are at
high risk for several cardiovascular disor-
ders, such as coronary artery disease,
stroke, peripheral arterial disease, cardio-
myopathy, and congestive heart failure
(11). These risks are particularly high in
patients with uremia and type 1 diabetes,
even after kidney transplantation (12). A
worsening of carotid lesion has been ob-
served in patients undergoing kidney-
alone transplantation (13). High levels of
von Willebrand factors (vWF) and D-
dimer fragments (DDFs), and impaired
endothelial-dependent dilation (EDD)
are commonly involved in development
of atherosclerosis (14). In particular, en-
dothelium modulates platelet adhesion,
macrophage migration, lipid transport,
and mitogenesis (14). Impairment of di-
lationability is an important predictor of
atherosclerosis and cardiovascular events
(13,14). Both diabetes and uremia are
conditions with increased proneness
toward impaired EDD and hemostasis ab-
normalities that could accelerate athero-
sclerosis (13,15–18).
Pancreas transplantation could slow
the progression of atherosclerosis and
could improve endothelial function in
uremic type 1 diabetic patients (13).
Recent studies have shown that exog-
enous C-peptide can improve neural
and vascular function in diabetic rats and
can restore nitric oxide (NO) synthase ex-
pression, which is impaired in diabetic
patients (19–23). Islet transplantation is
an appealing alternative to pancreas
transplantation, given that with classic
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immunosuppression a persistent C-
peptide secretion could be obtained for a
long period of time. Our aim was to eval-
uate whether islet transplantation could
affect survival, cardiovascular death rate,
and endothelial function in kidney-
transplanted type 1 diabetic patients.
RESEARCH DESIGN AND
METHODS
Patients
A total of 34 type 1 diabetic kidney-
transplanted patients underwent islet
transplantation and were followed for an
average of 53.4  7.09 months until 1
January 2001 or until they were lost to
follow-up due to exitus or other causes.
The general characteristics of the patients
before transplantation are summarized in
Table 1. All the patients were C-peptide
negative (0.5 ng/ml) before transplanta-
tion (Table 1). C-peptide levels reported
at each time of follow-up were assessed
during hospitalization. Exclusion criteria
for transplantation were as follows: 1)
previous strokes, 2) major amputations,
3) severe dilated cardiomyopathy, and 4)
coronary artery disease. Before transplan-
tation none of the patients had a patho-
logical ejection fraction or heart failure.
Furthermore, all of the patients who en-
tered the islet transplantation program at
our institute were carefully evaluated for
known cardiovascular risk factors. No
differences were evident with regards to
electrocardiogram, perfusional myocar-
dial scintigraphy, echocardiography, and
carotid and lower limb arterial status, as
evaluated by Doppler ultrasonography.
Patients were divided into two groups
according to the presence or absence of
C-peptide secretion: the successful islet-
kidney–transplanted (SI-K) group (fast-
ing C-peptide serum concentration 0.5
ng/ml for1 year, 21 patients, mean fol-
low-up 46  9 months) and the unsuc-
cessful islet-kidney–transplanted group
(UI-K) (fasting C-peptide serum concen-
tration 0.5 ng/ml, 13 patients, mean
follow-up 63  13 months).
All of the patients were evaluated for
cumulative survival, cardiovascular death
rate, C-peptide secretion, insulin require-
ment, and metabolic control. Subgroups
of patients underwent the following in-
vestigations aimed at studying the vascu-
lar function: 1) 24 patients (16 SI-K, 8
UI-K) were studied for EDD, NO levels,
atherothrombotic risk factors such as
vWF and DDF levels cross-sectionally; 2)
19 patients (13 SI-K, 6 UI-K) were studied
for intima-media thickness (IMT) pro-
gression; and 3) 12 patients (6 SI-K, 6
UI-K) underwent skin biopsy for patho-
logical examination, cross-sectionally. Pa-
tients were pooled together to perform
correlations between C-peptide–to–
creatinine ratio/HbA1c and parameters
under investigations. An informed con-
sent was obtained for every study.
Islet isolation and transplantation
Patients underwent kidney transplanta-
tion according to ABO match. Eight pa-
tients received simultaneous Langherans
islet transplantation, while the others re-
ceived islet transplantation after kidney
transplantation. Islets were isolated from
pancreas obtained from multiorgan do-
nors, according to a modification of the
automated method and purified by cen-
trifugation on a discontinuous gradient
previously described (4,24). Islets were
then cultured in a humidified atmosphere
(5% CO2) in M199 medium supple-
mented with 10% FCS, 100 units/ml pen-
icillin, 100 g/ml streptomycin sulfate,
and 2 mmol/l glutamine (Seromed Bio-
chrom, Berlin, Germany). Preparations
were considered adequate for transplan-
tation according to the following criteria:
1) sterility (aerobic, anaerobic, fungal,
and mycoplasm assessment); 2) number
of equivalent islets6,000/kg body wt; 3)
purity 20% (morphometric determina-
tion of islet/total mass); and 4) islet viabil-
ity. Transplantation was performed
between 12 and 48 h after isolation. Per-
cutaneous transhepatic injection (under
local anesthesia) was performed accord-
ing to the protocol approved by the Insti-
tutional Review Board. All patients were
already under immunosuppression ther-
apy with steroids and cyclosporine for a
previous kidney transplant. After
induction with ATG (125 mg/day for 10
days) (Thymoglobulin; Merieux, Lyon,
France) immunosuppression was based
on cyclosporine (7.5 mg  kg1  day1);
mycophenolate mofetil (2 g/day); and
metilprednisone (10 mg/day). Steroids
were withdrawn within 3–6 months after
islet transplantation.
Patient survival and cardiovascular
events
Patients actuarial survivals were calcu-
lated. Cardiovascular death rate was as-
sessed according to ICD-9.
IMT
Patients underwent ultrasonographic
analysis of IMT of the carotid artery (11)
3.1 0.5 years after islet transplantation.
The examinations were repeated 3 years
later and the variation of the IMT was cal-
culated. Ultrasonographic analysis of the
carotid artery was done with a high-
resolution ultrasound scanner (Acuson
128 Xp/10) equipped with a linear array
3.5- to 5-MHz transducer. Optimal axial
resolution is 	0.20 mm. The analysis
limited to the “far wall” of a restricted area
of common carotid artery was at least 1
cm below the bifurcation; the start of the
carotid bifurcation was evaluated as the
point of loss of parallel configuration of
the far and near wall. IMT was defined as
the distance from the leading edge of the
lumen-intima interface and the leading
edge of the media-adventitia interface of
the far wall. The mean of the right and the
left longitudinal common carotid artery
IMT measurements was used in the anal-
ysis. Intraobserver variability varied be-
tween a mean  SD difference of 0.02 
0.02 mm in selected and trained group
(13), which is quite similar to our
reproducibility.
Table 1—Pretransplant characteristics in type 1 diabetic kidney-transplanted patients with
successful islet transplantation (SI-K) or unsuccessful islet transplantation (UI-K)
SI-K group UI-K group P
n 21 13
Age (years) 41.2  1.3 40.6  3.8 NS
Sex (M/F) 11/10 11/2 0.04
C-peptide levels 0.14  0.02 0.15  0.03 NS
Duration of diabetes (years) 26.5  2.1 26.7  1.7 NS
Glycated hemoglobin (%) 8.1  0.2 7.7  0.6 NS
Body weight (kg) 59.7  2.0 59.3  3.1 NS
Data are mean  SEM. No differences were observed between the two groups except for sex distribution.
Islet transplantation and diabetic angiopathy
1130 DIABETES CARE, VOLUME 26, NUMBER 4, APRIL 2003
Skin biopsy
Patients underwent skin-punch biopsy on
the internal surface of the arm 4.5  1.2
years after transplantation (25). Micro-
vessel lesions were evaluated on routinely
stained paraffin-embedded sections. Two
different rabbit polyclonal antibodies di-
rected against the vWF (Dako, Copenha-
gen, Denmark and Biomeda, Hayward,
CA), and a polyclonal antibody directed
against endothelial constitutive NO syn-
thase (ecNOs) (Santa Cruz Biothecnology,
Santa Cruz, CA) were used. The immuno-
reactivity was independently scored by
two different pathologists (S.L. and S.U.)
on at least 10 capillaries. Anti-vWF and
anti-vimentin antibodies (Dako) were
used for immunoelectron microscopy ex-
periments (26). A score of endothelial cell
injury was calculated at ultra-structural
examination, each feature (rough endo-
plasmic reticulum, cisternae dilation,
microvilli ramification, vimentin-like fila-
ment, chromatine condensation, and ir-
regular nuclear contour) was evaluated
based on a scale from 0 (normal) to 3
(highly pathological).
Endothelial function, NO
production, and atherothrombotic
risk factors
Patients underwent EDD, NO, and
atherothrombotic risk factor assessment
4.2  0.9 years after transplantation.
EDD, circulating levels of vWF, DDF, and
NO levels were determined as previously
described (13,27,28). Patients were then
pooled together and the parameters of
endothelial function were correlated with
C-peptide and HbA1c. EDD was assessed
by evaluation of flow increase after hyper-
emia. Endothelial-independent dilation
was studied by vasodilation mediated by
nitrates. Anteroposterior diameter was
evaluated as parameters of endothelial
function. Diameter of the artery was pref-
erentially evaluated in B-mode. An oc-
cluding forearm cuff placed 5 cm below
the antecubital fossa was inflated to 50
mmHg above systolic pressure for 5 min
and then released to induce reactive local
hyperemia. Recordings were made 5, 60,
and 120 s after onset of reactive hyper-
emia and 3 min after sublingual adminis-
tration of nitroglycerine spray (400 mg).
In each case, the arm without shunt was
used for the test. Our reproducibility for
EDD performed in control groups ranged
from 2.5 to 3.0% (13).
Laboratory assessment
Fasting levels of cyclosporine, creatinine,
HbA1c, serum C-peptide, total choles-
terol, and triglycerides were assayed
yearly (13). Due to a potential confound-
ing effect of C-peptide renal clearance,
C-peptide is reported as C-peptide–to–
creatinine ratio. vWF was determined by
an immunoelectrophoresis method based
on the use of polyclonal goat IgG anti-
human vWF (American Diagnostic,
Greenwich, CT) (13). Serum C-peptide
levels (intra-assay CV 3.0%; interassay
CV 3.0%) were assayed by radioimmuno-
assy using commercial kits (Medical
System, Genova, Italy). NO levels were
assayed by measurement of the end prod-
ucts of their metabolism [i.e., nitrite and
nitrate levels (NO2-/NO3-)], using enzy-
matic catalysis coupled with Griess reac-
tion. Specifically, NO3- was reduced to
NO2- by 0.1 unit nitrate reductase, 5 

106 mol/l flavinadenine dinucleotide,
and 250
 106 mol/l nicotinamide ade-
nine dinucleotidephosphate (reduced
form). Samples were incubated at 37°C
for 3 h, 8.8 units lactate dehydrogenase
and 102 mol/l pyruvate were added to
each well, and the sample was incubated
for 90 min at 37°C. Finally, Griess reac-
tives were added to each well, and the
sample was read at 540 nm. The other
parameters were assessed with common
laboratory kit assay.
Statistical analyses
All the data were expressed as mean 
SEM. The cumulative survival was evalu-
ated with a Wilcoxon test. A multivariate
analysis (Cox analysis) was used to deter-
mine the effect of sex on survival. Differ-
ences between parameters were evaluated
using Student’s t test when parameters
were normally distributed, Mann-
Whitney U test when parameters were
not normally distributed, and a 2 test for
categorical variables. Correlations were
assessed with a Spearman rank correla-
tion coefficient.
RESULTS
General characteristics
Before transplantation, the two groups
were similar for the most important char-
acteristics (Table 1). No differences for
creatinine levels, fasting serum insulin,
lipid profile, arterial blood pressure, cy-
closporine levels, kidney rejection rate,
and smoking habits (data not shown)
were observed during the follow-up. A
statistical difference was evident for sys-
tolic blood pressure (SBP) at baseline
(SI-K 135.6  8.8 vs. UI-K 148.2  6.2
mmHg, P  0.04). However, this differ-
ence was no longer observed at 2 (SI-K
140.2 5.4 vs. UI-K 149.0 6.3 mmHg,
NS) and 4 years (SI-K 143.3  8.8 vs.
UI-K 150.0  6.2 mmHg, NS). Sex dis-
tribution appeared significantly different
in the two groups (Table 1). As shown,
the UI-K group has a longer follow-up
than the SI-K group, although not statis-
tically significant. The accrual rate in the
two groups during the whole follow-up
was similar except in 1991 (SI-K 0 vs.
UI-K 3, P  0.048) and in 2000 (SI-K 7
vs. UI-K 0, P  0.02). At the moment of
cross-sectional studies, no differences
were evident for creatinine (SI-K 1.3 
0.1 vs. UI-K 1.5  0.2 mg/dl), SBP (SI-K
143.3  8.8 vs. UI-K 148.8  5.6
mmHg), diastolic blood pressure (DBP)
(SI-K 83.3  3.6 vs. UI-K 84.4  2.4
mmHg), and lipid profile (data not
shown). Immunosuppression and medi-
cal treatment during the follow-up were
similar in the two groups.
Patient survival and cardiovascular
death rate
The SI-K group showed a statistically sig-
nificant (P 0.04) higher patient survival
than the UI-K group at 10 years (Fig. 1A).
A statistical difference was evident in sex
distribution between the SI-K and the
UI-K group (Table 1). However, analyz-
ing our data in a multivariate analysis
(Cox analysis), inserting sex as a cofactor,
does not appear to have a significant im-
pact on survival (P  0.89, relative risk
1.12 [95% CI 0.21–5.8]). Cardiovascular
death rate (according to ICD-9) was
higher in the UI-K group than in the SI-K
group (SI-K 1/21 vs. UI-K 4/13, 2 3.9,
P  0.04).
Glycometabolic control
C-peptide secretion was higher in the
SI-K group than in the UI-K group (Fig.
1B), insulin requirement was lower in the
SI-K group than in the UI-K group (Fig
1C), and no statistical difference in HbA1c
levels was observed in the two groups
(Fig. 1D).
IMT
A stabilization of IMT was observed in the
SI-K group (1–3 years 13  30 m),
Fiorina and Associates
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while IMT increased in the UI-K group
(1–3 years 245  20 m) (P  0.03).
Skin biopsy
Histopatology and immunohistochem-
istry. Morphologic evaluation of rou-
tinely stained sections from skin biopsy
specimens did not show any specific skin
disease apart from lesions of diabetic mi-
croangiopathy. In particular, periodic
acid Schiff stains demonstrated an in-
crease of basal membrane thickness of
dermal capillaries in both SI-K and UI-K
groups, with no significant differences be-
tween them. vWF and ecNOs immuno-
histochemical expression in endothelial
cells was higher in the SI-K than in the
UI-K group (Fig. 2).
Electron microscopy. The basal mem-
brane thickness was slightly lower in the
SI-K group than in the UI-K group (SI-K
1,488  276 vs. UI-K 1,628  790 nm,
NS). The endothelial cells of cutaneous
capillaries of the SI-K group showed
lower cell injury compared with capillar-
ies of the UI-K group. The endothelial
cells of the UI-K group showed microvil-
lar blebbing, dilated endoplasmic reticu-
lum (Fig. 3A and B), condensation of
vimentin filaments (Fig. 3C and D), and
irregular nuclear contour with chromatin
condensation more prominent than those
of the SI-K group (Fig. 3E and F). A global
score of microvascular/endothelium in-
jury was significantly better in the SI-K
group than in the UI-K group (Table 2).
Endothelial function, NO
production, and atherothrombotic
risk factors
The SI-K group showed a higher EDD
than the UI-K group (EDD [SI-K] 7.8 
4.5% vs. [UI-K] 0.5  2.7%, P  0.02),
higher basal NO level (SI-K 42.9 6.5 vs.
UI-K 20.2  6.8 mol/l, P  0.02), and
lower levels of vWF (SI-K 138.6  15.3
vs. UI-K 180.6  7.0%, P  0.02) and
DDF (SI-K 0.61  0.22 vs. UI-K 3.07 
0.68 g/ml, P  0.01). EDD and NO se-
rum levels positively correlated with C-
peptide–to– creatinine ratio (r  0.43,
P 0.04 and r 0.50, P 0.01, respec-
tively) while vWF and DDF serum levels
negatively correlated with C-peptide–to–
creatinine ratio (r0.51, P 0.01 and
r 0.74, P 0.01, respectively). None of
these parameters correlated with HbA1c.
The SI-K group was subdivided
according to higher or lower levels of
C-peptide (divided on the basis of 50 per-
centiles) (higher 1.30  0.16 vs. lower
3.27  0.62 ng/ml, P  0.01). Patients
with higher levels of C-peptide showed
normal EDD (higher 12.8 4.0 vs. lower
4.1 4.3%, NS), higher NO levels (high-
er 42.5 7.3 vs. lower 29.4 7.9 mol/l,
NS), and reduced vWF (higher 111.6 
16.8 vs. lower 164.8  22.9%, NS) and
DDF (higher 0.46 0.13 vs. lower 1.15
Figure 1—Patients cumulative survival (Wilcoxon test, P  0.04) (A), and mean HbA1c (B), C-peptide levels (C), and exogenous insulin
requirement (D) in type 1 diabetic kidney-transplanted patients with successful islet transplantation (SI-K) or failed islet transplantation (UI-K).
(*P  0.01, °P  0.05).
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0.80 g/ml, NS) levels, when compared
with patients with lower C-peptide levels.
CONCLUSIONS — Survival in ure-
mic type 1 diabetic patients undergoing
hemodialysis is extremely poor (12,29).
Kidney-pancreas transplantation doubles
life expectancy in these patients (12,29).
In this report we describe, for the first
time, the long-term beneficial effects of
islet transplantation on survival and mi-
cro- and macrovascular complications in
34 type 1 diabetic kidney-transplanted
patients at a single institution.
Survival in patients with functioning
islets is similar to kidney-pancreas–
transplanted patients, and is better than
in patients with nonfunctioning trans-
planted islets (12,29). Because of sex mis-
match, the results of our analysis on
patients’ survival in the UI-K and SI-K
groups have been reanalyzed in a multi-
variate analysis. Sex does not appear to be
a confounding factor for survival.
IMT is an important index for even-
tual cardiovascular disease. For each 100
m of IMT, the risk of acute myocardial
infarction increased by 11% (13). The
worsening of IMT in the UI-K group is
higher than the value observed in the gen-
eral population (30 m/3 years), but is
similar to the population with ischemic
heart disease (90–200 m/3 years) (30).
Islet function could play a role in prevent-
ing atherosclerosis and impairment of mi-
crovascular reactivity characteristics of
diabetes and related conditions (31). Al-
though no pretransplant analysis has
been performed for the variable that we
have studied in these patients, it is un-
likely that the data observed could be at-
tributed to differences at baseline. The
two groups were studied in detail and
were similar for major known cardiovas-
cular risk factors and status.
Endothelial function positively corre-
lates with C-peptide–to–creatinine ratio
but does not correlate with HbA1c levels.
Endothelial function reflects the ability of
the endothelium to produce NO, which is
impaired in uremia and in long-term hy-
perglycemia (22,32–34). As reported in
the rat model, restoration of C-peptide se-
cretion may protect endothelial function
via ecNOs activation (19). vWF and DDF
are well-established markers of endothe-
lial dysfunction and incipient atheroscle-
rosis (13). The higher levels of these two
soluble markers in the patients with lower
C-peptide levels suggest proneness to-
ward accelerated atherosclerosis.
Histology and immunohistochemis-
try of skin biopsies did not show major
morphological differences, although a re-
duced expression of vWF and ecNOs was
evident in the vessels of the UI-K group.
The alterations most frequently reported
in electron microscopy include thicken-
ing of the capillary basement membrane
(35), cell swelling, dilated endoplasmic
reticulum in endothelial cells, and sepa-
rations of interendothelial junctions
Figure 2—Immunohistochemical analysis of skin
biopsies performed in type 1 diabetic kidney-
transplanted patients with successful islet transplan-
tation (SI-K, no. 34) or failed islet transplantation
(UI-K, no. 3) (original magnification 200
). A:
Periodic acid Schiff in an SI-K patient. B: Periodic
acid Schiff in a UI-K patient. C: vWF vascular ex-
pression in an SI-K patient. D: vWF vascular ex-
pression in a UI-K patient. E: ecNOs vascular
expression in an SI-K patient. F: ecNOs vascular
expression in a UI-K patient.
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(35,36). Basal membranes were thicker in
the UI-K group than the SI-K group, per-
haps because of the continuous process of
endothelial cell death and regeneration
(35,37,38). Furthermore, accumulation
of bundles of vimentin filaments could be
considered a sign of degeneration or a
consequence of hemodynamic modifica-
tions (39). Our frequent observation of
nuclear irregular shapes, most frequent in
the UI-K group, can be explained either as
an aspect of endothelial damage (40) or as
a consequence of rearrangement in the vi-
mentin filaments. In fact, in many cells,
intermediate filaments are closely associ-
ated with the nucleus, suggesting a func-
tion in nuclear anchoring or signaling
(41). The presence of nuclear chromatine
condensation indicating apoptosis in en-
dothelial cells in the UI-K group is con-
sistent with previous studies showing a
role of hyperglycemia in the induction of
apoptosis in islet and endothelial cells
(26,41).
The beneficial effects of functioning
islets could be the consequence of an im-
proved metabolic control and of the res-
toration of islet endocrine function in
the SI-K group. Interestingly, during the
follow-up, the SI-K reached values of
HbA1c similar to those found by Diabetes
Control and Complications Trial to pre-
vent diabetic microvascular complica-
tions (9). The subanalysis in the SI-K
group suggests that there are some bene-
ficial effects of restoring islet endocrine
function, after splitting the patients into
two groups according to higher or lower
C-peptide levels. However, at this time it
is difficult to distinguish between effects
mediated by 1) improvement of glyco-
metabolic control, 2) restoration of islet
endocrine function, and 3) some unde-
tectable differences that might have been
present between the two groups, making
the SI-K group healthier than the UI-K
group.
Pancreas transplantation and, to a
lesser extent, islet transplantation reduce
insulin resistance in type 1 diabetic pa-
tients (42,43), which is a major risk factor
for cardiovascular disease (44). Islet graft
restoration of endogenous C-peptide se-
cretion may also play a beneficial effect
through the modulation of ecNOs. It is
also possible that C-peptide replacement
may prevent the development or retard
the progression of chronic complications
in type 1 diabetes by a variety of mecha-
nisms, including augmented blood flow
in skeletal muscle and skin, diminished
glomerular hyperfiltration, and improved
nerve function (45).
In conclusion, this study shows that
successful islet transplantation improves
the overall survival, cardiovascular out-
Figure 3—Electron microscopy analysis in type 1 diabetic kidney-transplanted patients with
successful islet transplantation (SI-K) or failed islet transplantation (UI-K). A: Microvilli rami-
fication and cisternae dilation in a SI-K patient (no. 13) (final magnification 13,000
). B:
Microvilli ramification and cisternae dilation in a UI-K patient, (no. 21) (final magnification
13,000
). C: Vimentin-like filament in an SI-K patient (no. 13) (final magnification 13,000
);
inset: anti-vimentin immunogold labeling (final magnification 22,000
). D: Vimentin-like fila-
ment in a UI-K patient (no. 21) (final magnification 13,000
); inset: anti-vimentin immunogold
labeling (final magnification 22,000
). E: Nuclear aspect and chromatine pattern in an SI-K
patient (no. 24) (final magnification 6,300
). F: Nuclear aspect and chromatine pattern in a UI-K
patient (no. 21) (final magnification 6,300
).
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comes, and endothelial function in type 1
diabetic kidney-transplanted patients.
We hypothesize that islet transplantation
could exert its beneficial effects, by not
only improving blood glucose control,
but also by partial restoration of endo-
crine islet function.
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